Mold-Tek Targets INR80–85cr Capex, Aiming 42–43 EBITDA/kg

Mold-Tek Packaging Limited — Q4 FY26 Earnings Call (held May 11, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly highlights “good results”, “healthy 13.4% growth”, “better EBITDA margins”, and “very positively for ’26-’27”.
• Forward-looking language is confident: “we are confident”, “we hope”, “look for higher numbers going forward”, and “aiming at… at least 42 to 43” EBITDA/kg.

2. Key Themes from Management Commentary

• Operational efficiency / consolidation benefits
• Consolidation of 5 Hyderabad units into 2 units (Unit 1 & 10) improved efficiencies and EBITDA margins.
• Automation and cost-control teams (finance/HR/admin) to monitor costs across units.
• Pharma is the growth engine
• Pharma packaging grew 37% YoY in Q4 and full-year growth “more than 200%”.
• Management is expanding pharma product range and expects pharma to scale meaningfully in FY27.
• Paint recovery led by ABG/Grasim and Asian Paints
• Paint shows double-digit growth; Asian Paints specifically cited as “more than 17% growth coming from Asian Paints in Q4 to Q4”.
• ABG/Grasim contribution described as strong; ABG volumes “more than 60%” YoY in Q4 (base effects acknowledged).
• Lubes remains a drag
• Lubes decline attributed to loss of BPCL tender (pricing-driven) and ongoing stagnation in the segment.
• Management expects lube to be stagnant/flat rather than a growth driver.
• Macro/war-related raw material volatility
• War impacted sentiment and raw material procurement; management claims clients are coming back due to Mold-Tek’s procurement/connectivity and ability to react.
• Capex discipline / brownfield focus
• Capex to reduce from prior years: ~INR140cr (two years ago) → ~INR120cr in FY25-26 → INR80–85cr in FY26-27, mainly brownfield.

3. Q&A Analysis

Theme A: Vibe Generation collaboration (closures for high-end chemicals/lubes)

• Core questions
• Whether Vibe contract contributed revenue in Q4.
• Whether pharma guidance includes Vibe revenue or is incremental.
• Management response
• Q4: pilot molds ready for 2 of 3 products; commercial revenue likely “towards the end of this financial year, ’26-’27”.
• Pharma guidance INR55cr–INR60cr is not including Vibe; it’s a separate pharma target.
• Notable / evasive elements
• Limited disclosure on commercial terms/margins; development timeline is clear, but financial magnitude and margin profile are not quantified in this call.

Theme B: Paint segment growth drivers & sustainability

• Core questions
• Break down paint growth with/without Grasim.
• Whether Asian Paints weakness has stabilized.
• What caused sharp paint volume/value changes.
• Management response
• Grasim/ABG contributed handsomely; ABG volumes >60% YoY in Q4.
• Asian Paints recovery: “more than 17% growth… in Q4 to Q4”.
• Sustainability: management claims growth is consistent and tied to IML adoption and customer commitments.
• Notable / partial answers
• With/without Grasim exact figures: not provided (“don’t have the figures readily available”).
• Some growth attribution relies on base effects (ABG “because this last year base was much smaller”).

Theme C: Lubes decline—extent, cause, and outlook

• Core questions
• Why lube decline is sharper than industry norms.
• Whether further volume loss is expected.
• Management response
• Main cause: lost BPCL tender due to inability to match L1 pricing; BPCL turnover ~INR14–15cr gone.
• Outlook: lube likely stabilize because no more PSU business to lose; private sector values quality/consistency.
• Notable / unusually strong answer
• “we may sustain at the current levels in Lubes” and “no more public sector units to lose” (implies limited downside, but doesn’t quantify probability).

Theme D: Capacity expansion, utilization, and capex

• Core questions
• Next year capacity from current utilization levels.
• Additional capacity targets in Pharma and Grasim.
• Whether capex reduction impacts growth.
• Management response
• FY27 capex targeted INR80–85cr; brownfield only.
• Capacity target: ~67k–68k tons, “maybe close to 70,000 tons” by end of FY27.
• Pharma capacity: from ~1,500 tons to ~2,500 tons (brownfield investments).
• Grasim capacity: ~12,000 tons created, running ~65% utilization now.
• Notable / partial
• Some capacity/utilization numbers are given, but segment-level utilization for FY27 is not fully reconciled across all plants.

Theme E: Margins, EBITDA/kg, and gross margin maintenance

• Core questions
• Can gross margin remain at 46–47% despite raw material volatility?
• EBITDA/kg targets for FY27 and FY28.
• Management response
• Claims full pass-through: “we have passed on the entire price rise to the clients”.
• EBITDA/kg guidance: FY27 42–43 (42.5 estimate); FY28 43–44 (with caveat “maybe difficult to predict now”).
• Management links margin improvement to consolidation efficiencies and higher utilization.
• Notable
• War-driven pricing pass-through described as “fair game”; however, they also acknowledge pricing corrections will move both directions (pass-through down too).

Theme F: Working capital / ROCE

• Core questions
• ROCE target vs historical 20% levels.
• Working capital days stretching—why and outlook.
• Management response
• ROCE improved: 10.2% → 12.4%, target 13.5–14% next year; 15% by ’27-’28.
• Working capital stretch attributed to high-price purchases, plus Pharma inventory/debtor cycles (90–110 days).
• Credibility note
• Explanation is plausible, but no hard working-capital metrics (days) were provided in this call.

4. Guidance / Outlook

Explicit guidance (quantitative)

• Pharma revenue target (FY26–27): INR55cr–INR60cr (stated as “target for the next financial year ’26-’27”).
• Overall sales growth (FY26–27):
• Volume growth: 10%–13% (management clarifies Pharma adds little in tons).
• Value growth: 13%–15%.
• Revenue milestone: “cross INR1,000 crores mark sales” in FY27; also hopes to cross INR1,200 crores by FY28 (implied in Q&A).
• EBITDA/kg:
• FY27: 42–43, with 42.5 as a “good estimate”.
• FY28: 43–44 range (with “maybe touch even 45” if Pharma performs well).
• EBITDA (company-level):
• FY27 EBITDA: INR210cr (up from INR173cr), ~20% growth.
• Capex:
• FY26–27 capex: INR80–85cr (brownfield focus).
• Capacity targets:
• Total capacity by end FY27: ~67k–68k tons, close to 70k.
• Panipat thin wall utilization outlook: from ~20–25% to ~40–50% next year (qualitative but with numbers).

Implicit signals (qualitative)

• Margin resilience: confidence that price pass-through will protect margins even with volatility.
• Demand stability: clients “coming back in herds” due to supply chain reliability concerns.
• Lubes: management expects stagnation/flat rather than recovery to prior run-rates.
• Pharma ramp: multiple new products/molds expected to contribute over “next 3–4 quarters”.

5. Standout Statements (direct / high-signal)

• Pharma growth & scaling
• “Pharma packaging… grown by 37% over the Q4 of last year” and “overall growth of the full year is more than 200%.”
• “INR55 crores is our target for the next financial year ’26-’27.”
• Margin confidence
• “Certainly, we have passed on the entire price rise to the clients across the segments.”
• “we can still continue to maintain our profit margins.”
• Lubes explanation
• “We lost a client BPCL… We couldn’t match their pricing and we let it go.”
• Capex discipline
• “We hope to control this capex to INR80 crores, INR85 crores in the next year… only brownfield expansions now onwards.”
• Client behavior under war
• “we are finding our clients coming back in herds… worried about connectivity, material procurement abilities…”
• EBITDA/kg guidance
• “FY ’27… aiming at, at least 42 to 43… 42.5 could be a good estimate.”

6. Red Flags / Positive Signals

Positive signals
– Clear operational levers: Hyderabad consolidation, automation, and utilization ramp tied to margin improvement.
– Pharma momentum is repeatedly reinforced with client visits, trials, and commercial pickups.
– Management provides specific drivers for lube decline (BPCL tender) rather than vague macro blame.

Red flags
– Some metrics are not fully reconciled:
– Capacity/utilization figures vary across answers (e.g., overall utilization references differ between calls/within call).
– Dependence on pass-through:
– Margin protection relies heavily on ability to pass raw material changes to customers; they acknowledge pass-through will also work both ways.
– Lubes outlook is “stagnant”:
– Could cap consolidated growth if paint/food/pharma ramp slows.
– Vibe collaboration financials remain under-disclosed:
– Timeline is given, but commercial magnitude/margins are not quantified in this call.

7. Historical Comparison & Consistency Analysis (vs prior calls)

a. Change in Tone Over Time

• Current call (Q4 FY26): More Optimistic
• Stronger confidence on FY27 targets (EBITDA/kg, EBITDA INR210cr, revenue >INR1,000cr).
• More emphasis on efficiencies already kicking in (“full benefit… reflective in next financial year”).
• Prior calls:
• Q3 FY26 (Feb 2026): optimistic but more conditional (“hopefully”, “we hope to catch up”); still discussing consolidation benefits “visible hopefully from next quarter”.
• Q2 FY26 (Oct 2025): more cautious around seasonality (rains/GST) and capacity utilization impacts.
• Shift classification: More Optimistic due to (i) consolidation benefits now translating into guidance, and (ii) pharma momentum accelerating.

b. Tracking Past Commitments vs Outcomes

• Pharma target progression
• Prior (Q2 FY26, Oct 2025): target to reach INR35+ crores in pharma; next year INR50–55 crores.
• Current (Q4 FY26): pharma full-year growth “more than 200%”; FY27 target reiterated INR55–60 crores.
• Assessment: ✅ Delivered/On track (management states current year pharma ~INR34.4cr and FY27 target aligns).
• Capex reduction
• Prior (Q3 FY26, Feb 2026): capex guidance next year INR80–85cr (after FY25-26 ~INR120cr; last year INR140cr).
• Current: repeats INR80–85cr.
• Assessment: ✅ Consistent / Delivered (no contradiction).
• Paint recovery narrative
• Prior (Q3 FY26): expected Asian Paints volumes to pick up after RCP settlement and rains easing.
• Current: Asian Paints recovery explicitly quantified (>17% growth in Q4 to Q4).
• Assessment: ✅ Delivered (at least in Q4; sustainability still claimed).
• Lubes stabilization
• Prior (Q3 FY26): lube decline explained by BPCL tender loss and monsoon; expectation to recover partially next year.
• Current: lube expected to stay at current levels and be stagnant.
• Assessment: ⏳ Partially delivered / narrative softened (from “recover loss” to “stagnant/flat”).

c. Narrative Shifts

• Pharma emphasis strengthened
• Earlier calls: pharma growth described as “on track” with trials and audits.
• Now: pharma is framed as a major growth engine with product expansion plans and stronger confidence.
• Lubes narrative becomes more structural
• Earlier: lube weakness partly cyclical/seasonal (monsoon, tender timing).
• Now: management frames it as stagnating market and “no more PSU units to lose,” implying limited upside.
• Client behavior under war becomes a new supporting narrative
• Not a major theme in earlier calls; now used to justify demand resilience.

d. Consistency & Credibility Signals

• Medium-to-High credibility
• Consistent capex guidance and pharma target range.
• Margin protection logic (pass-through + utilization + consolidation) is repeated and supported by EBITDA/kg guidance.
• Credibility caution
• Some “confidence” statements are broad and depend on external factors (“nothing further damage happens through this war”).
• Segment-level breakdowns are sometimes unavailable on the spot (e.g., with/without Grasim exact figures).

e. Evolution of Key Themes

• Demand
• Improving: from seasonality/rains/GST disruptions (Q2/Q3) → to “April strong momentum” and “clients coming back.”
• Margins
• Improving: EBITDA/kg guidance becomes more specific (42–43) and tied to consolidation benefits.
• Expansion
• Shift from greenfield completion talk (earlier) → brownfield-only capex discipline.
• Regulatory/Compliance
• RCP recycled plastic mandate becomes a cost/margin operational driver (maintenance cost increase; pharma exempt).

f. Additional Insights (cross-period intelligence)

• Utilization-driven margin story is tightening
• Q2/Q3 emphasized capacity utilization drops due to rains/GST.
• Q4 now claims consolidation benefits “full benefit… reflective in next financial year,” suggesting margins are less dependent on weather and more on structural efficiency.
• Lubes downside risk is being “contained” rather than “recovered”
• Management’s language shifts from recovery hopes to stabilization/stagnation—could indicate limited visibility on tender wins or pricing competitiveness.